Intelligence Report · ~12 min read
Heritage Pharma Intelligence Report
Generated from 2 signals · 2 evidence sources
Type
Company Intelligence ReportGenerated
Jul 21, 2026
Confidence
Moderate Confidence · 79%
Evidence
8 items
Sources
8
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Heritage Pharma maintains an active intelligence profile across Psychiatry, SSRI, Antipsychotic. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 79% across 2 tracked sources. Highest-priority development: FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Heritage Pharma.
Key Developments
Material intelligence events ranked by strategic relevance.
- regulatory
FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Withdrawn | Cancer Accelerated Approvals
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — RISPERIDONE (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
CDER proposes to withdraw approval of TAVNEOS
Regulatory precedent may inform portfolio positioning
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Opportunity score 40 with buyer quality 7 (Emerging). Competitive pressure: Low. Portfolio impact: High.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
Moderate Confidence · 65%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceGuidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations
Moderate Confidence · 66%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceOncology (Cancer)/Hematologic Malignancies Approval Notifications
High Confidence · 95%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceWithdrawn | Cancer Accelerated Approvals
High Confidence · 95%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — RISPERIDONE (SUPPL)
Moderate Confidence · 66%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceCDER proposes to withdraw approval of TAVNEOS
Moderate Confidence · 84%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- FDA Approval Update for Risperidone by Heritage Pharma
Psychiatry · Antipsychotic
- Heritage Pharma's Sertraline Hydrochloride ANDA Submission Receives AP Status
Psychiatry · SSRI